Tasimelteon (Hetlioz) for non-24-hour sleep-wake disorder

Medical Letter on Drugs and Therapeutics

Volumn 56, Issue 1441, 2014, Pages 34-35

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; HETLIOZ; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; RAMELTEON; RIFAMPICIN; TASIMELTEON; UNCLASSIFIED DRUG;

BEDTIME DOSAGE; BINDING AFFINITY; BLINDNESS; CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); DAYTIME SOMNOLENCE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INSOMNIA; LETTER; LIGHT DARK CYCLE; NIGHT SLEEP; NIGHTMARE; PARASOMNIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK FACTOR; SLEEP; SLEEP WAKING CYCLE; SMOKING; UNPLEASANT DREAM; URINE LEVEL;

BENZOFURANS; CYCLOPROPANES; HUMANS; RECEPTORS, MELATONIN; SLEEP; SLEEP DISORDERS, CIRCADIAN RHYTHM; TREATMENT OUTCOME;

EID: 84899151766     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. Ramelteon (Rozerem) for insomnia. Med Lett Drugs Ther 2005; 47:89.
2. Drugs for insomnia. Treat Guidel Med Lett 2012; 10:57.
3. RL Sack et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep 2007; 30:1484.
4. SA Ferguson et al. Melatonin agonists and insomnia. Expert Rev Neurother 2010; 10:305.
5. SW Lockley et al. Tasimelteon treatment entrains the circadian clock and demonstrates a clinically meaningful benefi t in totally blind individuals with non-24-hour circadian rhythms. The Endocrine Society 95th annual meeting (ENDO), San Francisco, June 15-18, 2013. Poster SUN-134.
6. SW Lockley et al. RESET study demonstrates that tasimelteon maintains entrainment of melatonin and cortisol in totally blind individuals with non-24-hour circadian rhythms. The Endocrine Society 95th annual meeting (ENDO), San Francisco, June 15-18, 2013. Poster SUN-137.
7. SM Rajaratnam et al. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomized controlled multicentre trials. Lancet 2009; 373:482.
8. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
9. Approximate wholesale acquisition cost (WAC). Source: Analy$ource® Monthly (Selected from FDB MedKnowledge™) April 5, 2014. Reprinted with permission by FDB, Inc. All rights reserved. ©2014. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher.